Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Al...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

Remy85 Aug. 7 at 2:20 PM

$AVXL has officially resubmitted its answers to the EMA, and the regulatory clock restarted on July 21, 2025 for the MAA of blarcamesine (Alzheimer’s). 👉 Based on standard EMA timelines: • CHMP opinion expected ~early November 2025 • Full EU marketing authorization likely by Dec 2025 / Jan 2026 If the CHMP delivers a positive opinion, this could be the first oral disease-modifying treatment for Alzheimer’s approved in Europe. Major catalyst ahead.

0 · Reply

MayoMobile Aug. 7 at 2:14 PM

$AVXL Will be making my post-AAIC quick-review video available this afternoon. Congrats to Anavex on their LoQ restart.

0 · Reply

junkjar291 Aug. 7 at 2:03 PM

$AVXL MAA review restarted as per schedule, that is new for this CEO, he is always late. Market still not pricing in approval.

1 · Reply

Logic102 Aug. 7 at 2:02 PM

$LLY Hey Eli, it's time to cut a deal with $AVXL while it's less expensive in the Alzheimer's/dementia prevention space. You have too much competition in weight loss. Time to expand your CNS presence. Blarcamesine would have Synergy with Kisunla and will treat the 75% of patients who can't tolerate a mAb.

2 · Reply

papatrick Aug. 7 at 2:00 PM

$AVXL i ll do my Georgii With such a great news, expect a huge drop and no volume today around the close! Bad Luck and Dog Blast

0 · Reply

nlrmandate Aug. 7 at 1:59 PM

$AVXL $VKTX take a gander $PFE

0 · Reply

Plexrec Aug. 7 at 1:55 PM

$AVXL Looks like "the street" can't read--par for the course !! Good news gets ignored-again !!

1 · Reply

ItsThrillhouse Aug. 7 at 1:50 PM

$AVXL Looks like all is well. 25 million shares just found out that the EMA gave one order in particular: Full Steam Ahead.

1 · Reply

steventrader7 Aug. 7 at 1:46 PM

$AVXL Shorts are trying the best to attack the stock . 1-2 months patience till they get exhausted

0 · Reply

papatrick Aug. 7 at 1:45 PM

$AVXL WOW!!!!

1 · Reply

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Jul 31, 2025, 7:30 AM EDT - 7 days ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

May 15, 2025, 8:49 PM EDT - 2 months ago

Does Anavex's Alzheimer's Drug Actually Confer Benefit?

May 15, 2025, 12:21 PM EDT - 2 months ago

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

May 14, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 9:25 AM EDT - 3 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 23, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 5, 2025, 11:30 AM EDT - 4 months ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 14, 2025, 6:02 PM EST - 6 months ago

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Feb 12, 2025, 3:13 PM EST - 6 months ago

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Feb 12, 2025, 9:59 AM EST - 6 months ago

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Feb 12, 2025, 7:30 AM EST - 6 months ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 5, 2025, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Jan 27, 2025, 7:30 AM EST - 6 months ago

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Jan 15, 2025, 7:30 AM EST - 7 months ago

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Jan 13, 2025, 7:30 AM EST - 7 months ago

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Jan 12, 2025, 11:21 AM EST - 7 months ago

Playing The Odds Of Anavex Alzheimer's Drug Approval

Jan 6, 2025, 7:30 AM EST - 7 months ago

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 7:30 AM EST - 7 months ago

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Dec 26, 2024, 10:31 AM EST - 7 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA PYPD

Dec 24, 2024, 8:50 AM EST - 8 months ago

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Dec 23, 2024, 10:23 AM EST - 8 months ago

Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript

Dec 23, 2024, 7:30 AM EST - 8 months ago

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Dec 23, 2024, 7:00 AM EST - 8 months ago

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Dec 16, 2024, 7:30 AM EST - 8 months ago

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Dec 9, 2024, 7:30 AM EST - 8 months ago

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 8 months ago

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Nov 26, 2024, 7:30 AM EST - 9 months ago

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA

Nov 25, 2024, 7:30 AM EST - 9 months ago

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

Nov 6, 2024, 5:10 AM EST - 9 months ago

Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario

Oct 31, 2024, 4:00 AM EDT - 10 months ago

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024

Oct 17, 2024, 7:30 AM EDT - 10 months ago

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 12:19 PM EDT - 1 year ago

Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

Jul 28, 2024, 5:00 PM EDT - 1 year ago

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 22, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Expansion of Leadership Team

May 14, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

May 13, 2024, 1:45 PM EDT - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $500,000 to Contact the Firm

Remy85 Aug. 7 at 2:20 PM

0 · Reply

MayoMobile Aug. 7 at 2:14 PM

$AVXL Will be making my post-AAIC quick-review video available this afternoon. Congrats to Anavex on their LoQ restart.

0 · Reply

junkjar291 Aug. 7 at 2:03 PM

$AVXL MAA review restarted as per schedule, that is new for this CEO, he is always late. Market still not pricing in approval.

1 · Reply

Logic102 Aug. 7 at 2:02 PM

2 · Reply

papatrick Aug. 7 at 2:00 PM

$AVXL i ll do my Georgii With such a great news, expect a huge drop and no volume today around the close! Bad Luck and Dog Blast

0 · Reply

nlrmandate Aug. 7 at 1:59 PM

$AVXL $VKTX take a gander $PFE

0 · Reply

Plexrec Aug. 7 at 1:55 PM

$AVXL Looks like "the street" can't read--par for the course !! Good news gets ignored-again !!

1 · Reply

ItsThrillhouse Aug. 7 at 1:50 PM

$AVXL Looks like all is well. 25 million shares just found out that the EMA gave one order in particular: Full Steam Ahead.

1 · Reply

steventrader7 Aug. 7 at 1:46 PM

$AVXL Shorts are trying the best to attack the stock . 1-2 months patience till they get exhausted

0 · Reply

papatrick Aug. 7 at 1:45 PM

$AVXL WOW!!!!

1 · Reply

steventrader7 Aug. 7 at 1:41 PM

$AVXL i feel 11:11 was prophetic

0 · Reply

g0eCK Aug. 7 at 1:39 PM

$AVXL Honestly, I am still wondering about the wording: and Dementia. For me it implies the potential use also for other dementias than alzheimers...

1 · Reply

Brian5220 Aug. 7 at 1:37 PM

$AVXL 7-21-2025 Restart !

7 · Reply

Greenspam Aug. 7 at 1:36 PM

$AVXL

0 · Reply

NoBagHoldingENT Aug. 7 at 1:32 PM

$AVXL $VKTX its only 4 companies in P3 for the biggest market in pharma history in Obesity. Lily, Novo, Viking, Amgen. I know you like your stock but please post sense or just stay on your board.

2 · Reply

Logic102 Aug. 7 at 1:31 PM

$AVXL Approval is confirmed now at over 95% positive odds after the restart at this phase for a non cancer drug. Share price is a ludicrous bargain. Mortgage the effing farm boys and girls.

0 · Reply

danielkazado Aug. 7 at 1:29 PM

$AVXL with the restart in the EMA approval process, we could have great news sooner than scheduled 🤩👍💪🏼

1 · Reply

imatrader65 Aug. 7 at 1:29 PM

$AVXL and GO! Our chances for approval just went up to 97% . People who know know what I’m talking about.

0 · Reply

chpr Aug. 7 at 1:25 PM

$AVXL https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-august-2025_en.xlsx Link to list

1 · Reply

chpr Aug. 7 at 1:20 PM

$AVXL chmp list is out. Restart after LoQ at 21. 7 2025!!!!!

4 · Reply

Logic102 Aug. 7 at 1:17 PM

$AVXL How undervalued are we? Look at $VKTX Viking with a 3.2 B Market Cap and a shipload of competition in weight loss. We are below 1 B with the massive unmet need for a safe, convenient, low side effect Alzheimer's pill for the masses. First to Market for Biotech's Holy Grail is coming.

2 · Reply

RunwtBulls Aug. 7 at 1:10 PM

$AVXL

0 · Reply

Market Cap	930.19M
Revenue (ttm)	0.00
Net Income (ttm)	-43.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	495,200
Avg Vol	1,036,332
Day's Range	N/A - N/A
Shares Out	85.42M
Stochastic %K	9%
Beta	0.80
Analysts	Strong Sell
Price Target	$44.00